GNPX - ジェンプレックス （Genprex Inc.） ジェンプレックスGNPXのチャート
GNPXの企業情報
| symbol | GNPx |
|---|---|
| 会社名 | Genprex Inc （ジェンプレックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Genprex Inc. is a clinical stage gene therapy company. The Company is focused on developing cancer-based upon its novel proprietary technology platform including its initial product candidate Oncoprex immunogene therapy or Oncoprex. The Company’s Oncoprex is lead product candidate is the subject of an ongoing Phase I/II clinical trials at The University of Texas MD Anderson Cancer Center in patients with late stage non-small cell lung cancer or NSCLC. Oncoprex gene therapy platform may also be effective with respect to other types of cancer including breast head and neck renal cell (kidney) soft tissue cancer. The Company’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles. The Company’s Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells re-establishes pathways for apoptosis. ジェンプレックスは米国のバイオ医薬品企業。臨床段階で、同社独自「Oncoprex」免疫療法を含むがん治療における遺伝子治療の開発に従事する。同社プラットフォ―ムは、がんを抑制する遺伝子を管理し、静脈内に投与され腫瘍に取り込まれたがん遺伝子が作るたんぱく質を発現する。同技術に関するテキサス大学がんセンタ―の特許を所有。本社はテキサス州オ―スティン。 Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company's lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca's Tagrisso®) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. |
| 本社所在地 | 1701 Trinity Street Suite 3.322 Austin TX 78712 USA |
| 代表者氏名 | J. Rodney Varner J.ロドニー・バナー |
| 代表者役職名 | Chairman of the Board Chief Executive Officer Secretary |
| 電話番号 | +1 512-708-0155 |
| 設立年月日 | 39904 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2018年 |
| 従業員数 | － |
| url | www.genprex.com |
| nasdaq_url | https://www.nasdaq.com/symbol/gnpx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -8.09860 |
| 終値（lastsale） | 2 |
| 時価総額（marketcap） | 30075888 |
| 時価総額 | 時価総額（百万ドル） 26.61716 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 14.61562 |
| 当期純利益 | 当期純利益（百万ドル） -8.13689 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Genprex Inc revenues was not reported. Net loss increased from $1.9M to $6.8M. Higher net loss reflects General and administrative increase from $1.8M to $6.6M (expense) Depreciation increase of 51% to $2K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.12 to -$0.51. |
GNPXのテクニカル分析
GNPXのニュース
Genprex to Present at Upcoming June Investor Conferences 2022/06/02 11:00:00 PR Newswire
Corporate Presentation to Highlight Company''s Gene Therapies for Cancer and Diabetes AUSTIN, Texas , June 2, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients…
Global Small-cell Lung Cancer Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight 2022/04/14 17:00:00 Benzinga
Las Vegas, USA, April 14, 2022 (GLOBE NEWSWIRE) -- Global Small-cell Lung Cancer Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight Small-cell Lung Cancer Pipeline constitutes 100+ key companies continuously working towards developing 100+ Small-cell Lung Cancer treatment therapies, analyzes DelveInsight DelveInsight''s Small-cell Lung Cancer Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Small-cell Lung Cancer pipeline domain. Some of the essential takeaways from the Small-cell Lung Cancer Pipeline report: DelveInsight''s Small-cell Lung Cancer Pipeline analysis depicts a robust space with 100+ active players working to develop 100+ Small-cell Lung Cancer treatment pipeline therapies. Some of the key Small-cell Lung Cancer companies proactively working to develop potential drug candidates to improve the Small-cell Lung Cancer treatment scenario include Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, Advanced Accelerator Applications, Trillium Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Aileron Therapeutics, Ipsen, Celgene, Lee''s Pharmaceutical Limited, AbbVie, Chipscreen Biosciences, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics, Amgen, Bristol-Myers Squibb, Genentech, Sorrento Therapeutics, DAIICHI SANKYO COMPANY, BioNTech, Harpoon Therapeutics, Genprex, Inc., Tarveda Therapeutics, Taizhou HoudeAoke Biomedical Co., Ltd., BeiGene, HaiHe Biopharma, Kartos Therapeutics, Inc., Boehringer Ingelheim, Y-mAbs Therapeutics, CStone Pharmaceuticals, EpicentRx, Inc., Pfizer, Mologen, Cybrexa Therapeutics, and many others.
This Biotech Company Has Cancer and Diabetes Treatments in Development 2022/01/31 22:04:14 The Street
Real Money''s Timothy Collins says Genprex has persevered in the face of successive setbacks.
Preclinical study suggests potential use of Genprex ONCOPREX in colon cancer 2022/01/27 17:32:12 Seeking Alpha
Genprex <> said its collaborators published positive preclinical data for the use of its ONCOPREX Nanoparticle Delivery System to deliver a FAS DNA plasmid to treat
Genprex Inc Shares Close the Week 69.5% Higher - Weekly Wrap 2022/01/08 18:38:38 Kwhen Finance
Genprex Inc (GNPX) shares closed this week 69.5% higher than it did at the end of last week. The stock is currently up 69.5% year-to-date, down 42.8% over the past 12 months, and down 52.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Shares traded as high as $3.62 and as low as $1.51 this week.Shares closed 71.2% below its 52-week high and 89.7% above its 52-week low.Trading volume this week was 67.5% lower than the 10-day average and 8.8% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.3. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 14.5% lower than its 5-day moving average, 34.1% higher than its 20-day moving average, and 2.7% higher than its 90-day moving average.
Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -26755.6% The company's stock price performance over the past 12 months lags the peer average by 389.0%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
This Biotech Company Has Cancer and Diabetes Treatments in Development 2022/01/31 22:04:14 The Street
Real Money''s Timothy Collins says Genprex has persevered in the face of successive setbacks.
Preclinical study suggests potential use of Genprex ONCOPREX in colon cancer 2022/01/27 17:32:12 Seeking Alpha
Genprex <> said its collaborators published positive preclinical data for the use of its ONCOPREX Nanoparticle Delivery System to deliver a FAS DNA plasmid to treat
Genprex Inc Shares Close the Week 69.5% Higher - Weekly Wrap 2022/01/08 18:38:38 Kwhen Finance
Genprex Inc (GNPX) shares closed this week 69.5% higher than it did at the end of last week. The stock is currently up 69.5% year-to-date, down 42.8% over the past 12 months, and down 52.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Shares traded as high as $3.62 and as low as $1.51 this week.Shares closed 71.2% below its 52-week high and 89.7% above its 52-week low.Trading volume this week was 67.5% lower than the 10-day average and 8.8% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.3. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 14.5% lower than its 5-day moving average, 34.1% higher than its 20-day moving average, and 2.7% higher than its 90-day moving average.
Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -26755.6% The company's stock price performance over the past 12 months lags the peer average by 389.0%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Proactive news headlines including Nextleaf Solutions, Genprex, Ready Set Gold, Sigma Lithium and Esports Entertainment 2021/06/23 18:40:00 Intrado Digital Media
New York , June 23, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies:
Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review 2021/06/23 12:30:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (Genprex or the Company) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the U.S. Food and Drug Administration (FDA) has reviewed and confirmed all comments have been addressed regarding the Companys clinical trial protocol for the Acclaim-1 clinical trial, an open-label, multi-center Phase 1/2 clinical trial evaluating the Companys
Analysts Estimate Report : What to Look Out for Genprex (NASDAQ:GNPX) 2021/05/20 19:56:00 Stock Market Daily
Earnings results for Genprex , Analyst Opinion on Genprex , Earnings and Valuation of (NASDAQ:GNPX), Stock market Insights & financial analysis, Best stock to invest, Investment Idea, The post Analysts Estimate Report : What to Look Out for Genprex (NASDAQ:GNPX) appeared first on .